Skip to content

PHARMA DAIVE: what changed

BE 0437.411.206NACE 47.730, Retail sale of pharmaceutical productsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€12,348
2024 · €41,689-€29,341
Equity
€148,683
2024 · €136,336+€12,348
Cash
€127,091
2024 · €89,951+€37,140
Balance sheet total
€247,671
2024 · €407,317-€159,646

Largest movements

2024 to 2025
Assets
  • Current investments -€199,306

    down €199,306 (-100.0%), from €199,333 to €27

  • Cash +€37,140

    up €37,140 (+41.3%), from €89,951 to €127,091

    mainly Current investments (+€199,306) and Net result for the year (+€12,348)

  • Receivables within one year +€4,808

    up €4,808 (+8.2%), from €58,451 to €63,259

    of which Other amounts receivable: +€42,238

Equity and liabilities
  • Other debts -€134,501

    no longer reported in 2025; in 2024 it stood at €134,501

  • Tax, wage and social debts -€32,913

    down €32,913 (-59.7%), from €55,122 to €22,209

    of which Taxes: -€32,378

  • Profit (loss) carried forward +€12,348

    up €12,348 (+100%), from €12,336 to €24,683

  • Trade debts -€4,580

    down €4,580 (-5.6%), from €81,358 to €76,778

Income statement
  • Financial income -€31,595

    down €31,595 (-97.2%), from €32,519 to €924

  • Taxes -€17,022

    down €17,022 (-79.9%), from €21,314 to €4,291

  • Gross operating margin -€13,132

    down €13,132 (-17.0%), from €77,430 to €64,298

  • Staff costs +€1,524

    up €1,524 (+3.5%), from €43,688 to €45,212

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 €41,689
Gross operating margin -€13,132
Staff costs -€1,524
Depreciation -€34
Other operating charges -€92
Financial income -€31,595
Financial charges +€13
Taxes +€17,022
Result 2025 €12,348
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations -€160,178
Investment +€197,318
Financing €0
Cash 2024 €89,951
Net result for the year +€12,348
Depreciation +€2,067
Stocks and contracts +€2,775
Receivables within one year -€4,808
Deferred charges and accrued income -€565
Trade debts -€4,580
Tax, wage and social debts -€32,913
Other debts -€134,501
Investment in fixed assets (net) -€1,988
Current investments +€199,306
Cash 2025 €127,091
brings cash intakes cash out
Every line side by side 43 lines
Line Code 2024 2025 Change %
Total assets 20/58 €407,317 €247,671 -€159,646 -39.2%
Fixed assets 21/28 €13,130 €13,051 -€78 -0.6%
Tangible fixed assets 22/27 €12,836 €12,758 -€78 -0.6%
Land and buildings 22 €807 €753 -€54 -6.7%
Plant, machinery and equipment 23 €1,901 €1,267 -€634 -33.3%
Other tangible fixed assets 26 €10,128 €10,737 +€609 +6.0%
Financial fixed assets 28 €294 €294 = 0.0%
Current assets 29/58 €394,187 €234,620 -€159,567 -40.5%
Stocks and contracts in progress 3 €43,297 €40,522 -€2,775 -6.4%
Stocks 30/36 €43,297 €40,522 -€2,775 -6.4%
Amounts receivable within one year 40/41 €58,451 €63,259 +€4,808 +8.2%
Trade receivables 40 €58,451 €21,021 -€37,430 -64.0%
Other amounts receivable 41 - €42,238 +€42,238
Current investments 50/53 €199,333 €27 -€199,306 -100.0%
Cash at bank and in hand 54/58 €89,951 €127,091 +€37,140 +41.3%
Deferred charges and accrued income 490/1 €3,155 €3,720 +€565 +17.9%
Total equity and liabilities 10/49 €407,317 €247,671 -€159,646 -39.2%
Equity 10/15 €136,336 €148,683 +€12,348 +9.1%
Contributions 10/11 €10,000 €10,000 = 0.0%
Reserves 13 €114,000 €114,000 = 0.0%
Distributable reserves 133 €114,000 €114,000 = 0.0%
Profit (loss) carried forward 14 €12,336 €24,683 +€12,348 +100%
Amounts payable 17/49 €270,981 €98,988 -€171,993 -63.5%
Amounts payable within one year 42/48 €270,981 €98,988 -€171,993 -63.5%
Trade debts 44 €81,358 €76,778 -€4,580 -5.6%
Suppliers 440/4 €81,358 €76,778 -€4,580 -5.6%
Taxes, remuneration and social security 45 €55,122 €22,209 -€32,913 -59.7%
Taxes 450/3 €49,595 €17,217 -€32,378 -65.3%
Remuneration and social security 454/9 €5,527 €4,992 -€535 -9.7%
Other amounts payable 47/48 €134,501 - -€134,501
Remuneration, social security and pensions 62 €43,688 €45,212 +€1,524 +3.5%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €2,033 €2,067 +€34 +1.7%
Other operating charges 640/8 €746 €837 +€92 +12.3%
Gross operating margin 9900 €77,430 €64,298 -€13,132 -17.0%
Operating profit (loss) 9901 €30,964 €16,182 -€14,782 -47.7%
Financial income 75/76B €32,519 €924 -€31,595 -97.2%
Recurring financial income 75 €32,519 €924 -€31,595 -97.2%
Financial charges 65/66B €480 €467 -€13 -2.7%
Recurring financial charges 65 €480 €467 -€13 -2.7%
Profit (loss) for the period before taxes 9903 €63,003 €16,639 -€46,364 -73.6%
Income taxes 67/77 €21,314 €4,291 -€17,022 -79.9%
Profit (loss) for the period 9904 €41,689 €12,348 -€29,341 -70.4%
Profit (loss) for the period to be appropriated 9905 €41,689 €12,348 -€29,341 -70.4%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€149,702 to €179,847

Midpoint €162,263 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

Adjusted equity €148,683
Capitalised earnings €150,721 to €211,010
Indication €149,702 to €179,847

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€148,683
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€148,683

Capitalised earnings

net result for the year (9904)
2025
€12,348
2024
€41,689
2023
€9,267
2022
€50,417
excluding non-recurring income and charges
€68,530
2021
€5,825
Average result
€21,101
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€150,721 / €175,842 / €211,010

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 15 November 2026 via checked.be.